Berberine for Health & Longevity - Quick Reference Sheet

Berberine for Health & Longevity

Created on 07/16/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 4.8 Audit

Berberine is a plant compound taken by mouth for blood-sugar and cholesterol control, where its effects are strongest and most repeatedly shown, resembling some standard drugs over a few months. Benefits for fatty liver, insulin resistance, and inflammation are modest, and weight loss is small. Claims about slowing aging stay unproven. Main cautions: digestive upset and altering other medicines' levels. (Full Review)

Protocol

Standard Dose
500 mg, 2–3×/day
Total 1,000–1,500 mg per day
Timing
With meals
Taken with the largest carbohydrate-containing meals
Dosing Schedule
Split doses
Divided across the day owing to short plasma half-life
Time to effect
Blood Sugar
Days to weeks
Initial glucose-lowering effects begin
Long-Term Blood Sugar
~8–12 weeks
Meaningful HbA1c change assessed
Cholesterol & Lipids
~8–12 weeks
Assessed after consistent use

Benefits

Contraindications
  • Pregnancy
  • Breastfeeding
  • Neonates and infants
  • Scheduled surgery
Key Interactions
  • Immunosuppressants (cyclosporine)
  • Statins (simvastatin, atorvastatin)
  • Blood thinners (warfarin, dabigatran)
  • CYP2D6 substrates (metoprolol, fluoxetine, paroxetine)
  • P-glycoprotein substrates (digoxin)
  • Antidiabetic drugs and glucose-lowering supplements
  • Antihypertensive drugs and blood-pressure-lowering supplements
  • Metformin and other AMPK-related agents

Risk & Side Effects

  • High: Gastrointestinal upset; clinically significant drug interactions
  • Medium: Hypoglycemia when combined with antidiabetic therapy; fetal and neonatal harm; additive hypotension
  • Low: Cardiac rhythm effects; transient liver enzyme changes
  • Speculative: Unknown long-term safety; potential adverse microbiome shifts

Monitoring

Marker Target Why
Fasting glucose 70–85 mg/dL Tracks the core glucose-lowering effect
HbA1c Below 5.4% Average blood sugar over ~3 months
Fasting insulin / HOMA-IR Insulin ~2–5 µIU/mL; HOMA-IR below 1.0 Detects insulin resistance and its improvement
Lipid panel with ApoB ApoB below 80 mg/dL; triglycerides below 80 mg/dL Captures the cholesterol and triglyceride response
ALT / AST ALT below 25 U/L Monitors liver effects, benefit and rare enzyme rises
Total bilirubin 0.3–1.2 mg/dL Bilirubin-related safety check
hs-CRP Below 1.0 mg/L (optimal below 0.5) Tracks systemic inflammation
Creatinine / eGFR eGFR above 90 mL/min/1.73m² Confirms kidney function for safe long-term use

Cadence: Baseline before the first dose; first metabolic re-check at 8–12 weeks; then every 3–6 months during continued use, with liver and kidney function reviewed at least annually.

Qualitative Assessment

  • Energy and post-meal comfort: steadier energy and less post-meal sluggishness or crashes
  • Digestive tolerance: presence or absence of diarrhea, constipation, or cramping
  • Appetite and cravings: changes in carbohydrate cravings and satiety
  • Cognitive clarity: subjective focus and mental sharpness